Inhibrx Biosciences, Inc.
INBX Healthcare Biotechnology
Inhibrx Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.3 million, up 550.0% from fiscal 2024. In the quarter to June 2026, revenue grew 992.4%, EPS fell 26.5%, free cash flow was flat and total debt rose 77.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow INBX
Inhibrx Biosciences, Inc. (INBX) P/E ratio
Inhibrx Biosciences, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.2× (September 2024) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.1× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2025 | 0.0× | — |
| Dec 2024 | 0.1× | 2.14% |
| Jun 2024 | 0.1× | — |
| Dec 2023 | 0.0× | — |
| 2 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| GHRS GH Research PLC compare | n/m |
| TYRA Tyra Biosciences, Inc. compare | n/m |
| NKTR Nektar Therapeutics compare | n/m |
| DRTS Alpha Tau Medical Ltd. compare | n/m |
| ORIC Oric Pharmaceuticals, Inc. compare | n/m |
| INBX Inhibrx Biosciences, Inc. | n/m |
| RAPP Rapport Therapeutics, Inc. compare | n/m |
| OMER Omeros Corporation compare | 9.5× |
| AAPG Ascentage Pharma Group International - Unsponsored ADR compare | — |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)